Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function.

Curran HV, Verheyden SL.

Psychopharmacology (Berl). 2003 Aug;169(1):91-103. Epub 2003 May 21.

PMID:
12759801
2.

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.

J Psychopharmacol. 2006 Mar;20(2):211-25. Review.

PMID:
16510479
4.
5.

The neuropsychology of ecstasy (MDMA) use: a quantitative review.

Zakzanis KK, Campbell Z, Jovanovski D.

Hum Psychopharmacol. 2007 Oct;22(7):427-35. Review.

PMID:
17896346
6.

The harmful health effects of recreational ecstasy: a systematic review of observational evidence.

Rogers G, Elston J, Garside R, Roome C, Taylor R, Younger P, Zawada A, Somerville M.

Health Technol Assess. 2009 Jan;13(6):iii-iv, ix-xii, 1-315. doi: 10.3310/hta13050. Review.

7.

Ecstasy (MDMA): a review of its possible persistent psychological effects.

Morgan MJ.

Psychopharmacology (Berl). 2000 Oct;152(3):230-48. Review.

PMID:
11105933
8.
9.

Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review.

Montoya AG, Sorrentino R, Lukas SE, Price BH.

Harv Rev Psychiatry. 2002 Jul-Aug;10(4):212-20. Review.

PMID:
12119307
10.

Long term psychiatric and cognitive effects of MDMA use.

McGuire P.

Toxicol Lett. 2000 Mar 15;112-113:153-6. Review.

PMID:
10720725
11.

The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.

Gouzoulis-Mayfrank E, Daumann J.

J Psychopharmacol. 2006 Mar;20(2):188-93. Review.

PMID:
16510477
12.

MDMA use and neurocognition: a meta-analytic review.

Kalechstein AD, De La Garza R 2nd, Mahoney JJ 3rd, Fantegrossi WE, Newton TF.

Psychopharmacology (Berl). 2007 Jan;189(4):531-7. Epub 2006 Nov 3. Review.

PMID:
17082969
13.

The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.

Karlsen SN, Spigset O, Slørdal L.

Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):15-24. Epub 2007 Nov 28. Review.

14.

How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?

Kish SJ.

Pharmacol Biochem Behav. 2002 Apr;71(4):845-55. Review.

PMID:
11888575
15.

A review of the acute subjective effects of MDMA/ecstasy.

Baylen CA, Rosenberg H.

Addiction. 2006 Jul;101(7):933-47. Review.

PMID:
16771886
16.

Neuroimaging research in human MDMA users: a review.

Cowan RL.

Psychopharmacology (Berl). 2007 Jan;189(4):539-56. Epub 2006 Jul 18. Review.

PMID:
16847678
17.

Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

Green AR, Cross AJ, Goodwin GM.

Psychopharmacology (Berl). 1995 Jun;119(3):247-60. Review.

PMID:
7675958
18.

Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings.

Pacifici R, Zuccaro P, Farré M, Pichini S, Di Carlo S, Roset PN, Palmi I, Ortuño J, Menoyo E, Segura J, de la Torre R.

Ann N Y Acad Sci. 2002 Jun;965:421-33. Review.

PMID:
12105117
19.

The effects of 'ecstasy' (MDMA) on visuospatial memory performance: findings from a systematic review with meta-analyses.

Murphy PN, Bruno R, Ryland I, Wareing M, Fisk JE, Montgomery C, Hilton J.

Hum Psychopharmacol. 2012 Mar;27(2):113-38. doi: 10.1002/hup.1270. Review.

PMID:
22389076
20.

MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational 'Ecstasy' users.

Parrott AC.

Neurosci Biobehav Rev. 2013 Sep;37(8):1466-84. doi: 10.1016/j.neubiorev.2013.04.016. Epub 2013 May 6. Review.

PMID:
23660456

Supplemental Content

Support Center